Gibson, Dunn & Crutcher advised Fairmount Funds on the deal. Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or the “Company”), a clinical-stage pharmaceutical company, announced the pricing...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here